SIGRID's Glucose Stabiliser demonstrates clinical efficacy and strong sales growth in the US – meeting growing global demand for natural solutions for metabolic health

Stockholm, Sweden – June 9, 2025. SIGRID, the Swedish innovative consumer health company behind the patented SiPore® technology, today reports new clinical and commercial milestones for its innovative dietary supplement Glucose Stabiliser. A recent clinical study with continuous glucose monitoring, together with a consumer test in the US, confirms the product’s ability to support blood sugar balance, appetite control, and contribute to improved satiety and reduced bloating – without affecting the body systemically.

At the same time, strong sales figures in the US show that the product meets a clear need among consumers seeking natural and science-based alternatives to traditional treatments.

Clinical study shows clear improvement in blood sugar balance

A 14-day, placebo-controlled, single-blind crossover study in 20 healthy adults (18–64 years) who wore continuous glucose monitors (CGM) during two phases

showed:
- Significantly longer time in optimal glucose range with Glucose Stabiliser ( p=0.01 vs. placebo)
- 85% fewer hypoglycemic episodes, indicating improved metabolic stability ( p=0.004 )

“ The study confirms our mechanism of action meal by meal. Participants were in optimal range almost 100% of the time with Glucose Stabiliser and reported a clear sense of balance and control. This is science that feels good – and whose effect can be measured ,” says Sana Alajmovic, co-founder and CEO of SIGRID.

Consumer tests in the US show effectiveness after just a few days

In a consumer test with 152 existing customers in the US, a majority reported clear improvements in digestion and appetite regulation after just a few days of use:

- 93% felt fuller for longer after meals
- 89% experienced reduced sugar cravings/need to snack
- 92% of users with bloating reported relief

The results underscore the product's role in promoting improved satiety and less bloating – important factors for daily well-being.

Strong growth in the US market

SIGRID's insights from clinical and consumer testing are reflected in sales. In May 2025, the company achieved its fifth consecutive month of growth in the US. Key figures include:

- +41% net sales compared to April
- +18% growth in sales to new customers
- 68% gross margin, driven by recurring subscription revenue
- 4% lower customer acquisition cost (CAC)

At the same time, advertising on the Meta platforms has delivered improved efficiency and conversion.

" These figures show that we are both delivering clinically validated effects and managing to engage a broad consumer group in a competitive market. SIGRID is well positioned for continued profitable expansion ," Alajmovic continues.